As shown in Figure 9A,B, this accounts for more than 12% of NSCLC patients, which exhibited modifications in the five TFAP2 family genes, including mutations (7.7%), amplifications (3.9%), deep deletions (0.3%), and multiple alterations (0.4%). This evidence concerns the gene TFAP2A and non-small cell lung carcinoma.